Top

Published in:

01-04-2020 | Breast Cancer | Clinical Trial

Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients

Authors: Minsung Kim, Hanna Kim, Sei Hyun Ahn, Vafa Tabatabaie, Sung Wook Choi, Guiyun Sohn, Sae Byul Lee, Beom Seok Ko, Il Yong Chung, Jisun Kim, Jong Won Lee, Byung Ho Son, Hee Jeong Kim

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Abstract

Purpose

Adjuvant treatment for breast cancer in postmenopausal women is a risk factor for bone loss. However, the association between bone mineral density (BMD) changes in premenopausal breast cancer patients and various adjuvant treatment regimens is not well characterized. In this study, we evaluated the changes in BMD according to adjuvant treatment in premenopausal women with breast cancer.

Methods

Between 2006 and 2010, BMD data of 910 premenopausal women with breast cancer before operation and 1, 2, 3.5, and 5 years post-operation were retrospectively analyzed. The patients were divided according to the type of treatment: observation (O), tamoxifen (T), chemotherapy (C), C followed by T (C → T), and gonadotropin-releasing hormone (GnRH) agonist with T (G + T).

Results

After 5 years of follow-up, BMD changes were similar between the T and O groups (all p > 0.05). Within 1 year of treatment, the C group showed the most significant BMD loss. The C → T and G + T groups showed more significant BMD loss in the lumbar spine and femur than the O and T groups (both p < 0.001, both). After 1 year of treatment, BMD loss in the lumbar spine was significantly greater in the C → T and G + T groups than in the T group; this tendency was maintained for 5 years of treatment (all p < 0.005).

Conclusion

Premenopausal women who received adjuvant treatment which induced menopause showed significant bone loss which lasted for 5 years. Although no significant difference was observed between the O and T groups, tamoxifen treatment during chemotherapy or GnRH agonist treatment might prevent bone loss.

Available only for authorised users

Vehmanen L, Elomaa I, Blomqvist C, Saarto T (2006) Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 24(4):675–680. https://doi.org/10.1200/JCO.2005.02.3515 CrossRefPubMed

Cameron DA, Douglas S, Brown JE, Anderson RA (2010) Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? Breast Cancer Res Treat 123(3):805–814. https://doi.org/10.1007/s10549-010-0899-7 CrossRefPubMed

Doo L, Shapiro CL (2013) Skeletal manifestations of treatment of breast cancer on premenopausal women. Curr Osteoporos Rep 11(4):311–318. https://doi.org/10.1007/s11914-013-0181-0 CrossRefPubMed

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy (2001). JAMA 285(6):785–795. https://doi.org/10.1001/jama.285.6.785

Richelson LS, Wahner HW, Melton LJI, Riggs BL (1984) Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 311(20):1273–1275. https://doi.org/10.1056/nejm198411153112002 CrossRefPubMed

Sverrisdóttir Á, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE (2004) Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22(18):3694–3699. https://doi.org/10.1200/jco.2004.08.148 CrossRefPubMed

Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A (1990) Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61(2):308–310CrossRef

Lester J, Coleman R (2005) Bone loss and the aromatase inhibitors. Br J Cancer 93(Suppl 1):S16–S22. https://doi.org/10.1038/sj.bjc.6602691 CrossRefPubMedPubMedCentral

Rodriguez-Sanz M, Prieto-Alhambra D, Servitja S, Garcia-Giralt N, Garrigos L, Rodriguez-Morera J, Albanell J, Martinez-Garcia M, González I, Diez-Perez A, Tusquets I, Nogues X (2016) AI-related BMD variation in actual practice conditions: a prospective cohort study. Endocr Relat Cancer. https://doi.org/10.1530/erc-16-0025 CrossRefPubMed

10.

Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326(13):852–856. https://doi.org/10.1056/NEJM199203263261302 CrossRefPubMed

11.

Powles TJ, Ashley S, Tidy VA, Nevantaus A, McCloskey E, Kanis J, Paterson AHG, Rosenqvist K (1998) Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90(9):704–708. https://doi.org/10.1093/jnci/90.9.704 CrossRefPubMed

12.

Burstein HJ, Lacchetti C, Griggs JJ (2016) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression summary. J Oncol Pract 12(4):390–393. https://doi.org/10.1200/jop.2016.011239 CrossRefPubMed

13.

Sohn G, Ahn SH, Kim HJ, Son B-H, Lee JW, Ko BS, Lee Y, Lee SB, Baek S (2016) Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with lymph-node-negative, hormone-responsive, HER2-negative, T1–T2 breast cancer. Cancer Res Treat 48(4):1351–1362. https://doi.org/10.4143/crt.2015.444 CrossRefPubMedPubMedCentral

14.

Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CEJ, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436–446. https://doi.org/10.1056/NEJMoa1412379 CrossRefPubMed

15.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Kielanowska J, Kwan W-H, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816. https://doi.org/10.1016/S0140-6736(12)61963-1 CrossRefPubMedPubMedCentral

16.

Armstrong MEG, Spencer EA, Cairns BJ, Banks E, Pirie K, Green J, Wright FL, Reeves GK, Beral V, for the Million Women Study C (2011) Body mass index and physical activity in relation to the incidence of hip fracture in postmenopausal women. J Bone Miner Res 26(6):1330–1338. https://doi.org/10.1002/jbmr.315 CrossRefPubMed

17.

Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the national osteoporosis risk assessment. JAMA 286(22):2815–2822. https://doi.org/10.1001/jama.286.22.2815 CrossRefPubMed

18.

Chrischilles EA, Butler C, Davis CS, Wallace RB (1991) A model of lifetime osteoporosis impact. Arch Intern Med 151(10):2026–2032. https://doi.org/10.1001/archinte.1991.00400100100017 CrossRefPubMed

19.

Siris ES, Chen Y, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164(10):1108–1112. https://doi.org/10.1001/archinte.164.10.1108 CrossRefPubMed

20.

Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118. https://doi.org/10.1056/NEJMoa1404037 CrossRefPubMedPubMedCentral

21.

Tabatabai LS, Bloom J, Stewart S, Sellmeyer DE (2016) FSH levels predict bone loss in premenopausal women treated for breast cancer more than one year after treatment. J Clin Endocrinol Metab 101(3):1257–1262. https://doi.org/10.1210/jc.2015-3149 CrossRefPubMedPubMedCentral

22.

Cauley JA (2015) Estrogen and bone health in men and women. Steroids 99:11–15. https://doi.org/10.1016/j.steroids.2014.12.010 CrossRefPubMed

23.

Compston J (2013) Obesity and bone. Curr Osteoporos Rep 11(1):30–35. https://doi.org/10.1007/s11914-012-0127-y CrossRefPubMed

24.

Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339(22):1609–1618. https://doi.org/10.1056/nejm199811263392207 CrossRefPubMed

25.

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840–849. https://doi.org/10.1016/S1470-2045(08)70204-3 CrossRefPubMed

26.

Gnant MFX, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R (2007) Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25(7):820–828. https://doi.org/10.1200/jco.2005.02.7102 CrossRefPubMed

27.

Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19(14):3306–3311CrossRef

28.

Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 15(3):955–962CrossRef

29.

Leslie WD (2012) Ethnic differences in bone mass—clinical implications. J Clin Endocrinol Metab 97(12):4329–4340. https://doi.org/10.1210/jc.2012-2863 CrossRefPubMed

Title: Changes in bone mineral density during 5 years of adjuvant treatment in premenopausal breast cancer patients
Authors: Minsung Kim
Hanna Kim
Sei Hyun Ahn
Vafa Tabatabaie
Sung Wook Choi
Guiyun Sohn
Sae Byul Lee
Beom Seok Ko
Il Yong Chung
Jisun Kim
Jong Won Lee
Byung Ho Son
Hee Jeong Kim
Publication date: 01-04-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Tamoxifen
GnRH Agonists
Cytostatic Therapy
Published in: Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05566-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer

Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy

Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy

The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience

Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers

Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls

Keynote webinar | Spotlight on antibody–drug conjugates in cancer